171 related articles for article (PubMed ID: 11336350)
21. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies.
Gabizon A; Shmeeda H; Barenholz Y
Clin Pharmacokinet; 2003; 42(5):419-36. PubMed ID: 12739982
[TBL] [Abstract][Full Text] [Related]
22. Endoplasmic reticulum and Golgi apparatus are the preferential sites of Foscan localisation in cultured tumour cells.
Teiten MH; Bezdetnaya L; Morlière P; Santus R; Guillemin F
Br J Cancer; 2003 Jan; 88(1):146-52. PubMed ID: 12556974
[TBL] [Abstract][Full Text] [Related]
23. Mitochondrial localization and activity of P-glycoprotein in doxorubicin-resistant K562 cells.
Munteanu E; Verdier M; Grandjean-Forestier F; Stenger C; Jayat-Vignoles C; Huet S; Robert J; Ratinaud MH
Biochem Pharmacol; 2006 Apr; 71(8):1162-74. PubMed ID: 16499877
[TBL] [Abstract][Full Text] [Related]
24. Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin.
Nakamura H; Koziolová E; Chytil P; Tsukigawa K; Fang J; Haratake M; Ulbrich K; Etrych T; Maeda H
Mol Pharm; 2016 Dec; 13(12):4106-4115. PubMed ID: 27934482
[TBL] [Abstract][Full Text] [Related]
25. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
[TBL] [Abstract][Full Text] [Related]
26. Distribution of furamidine analogues in tumor cells: targeting of the nucleus or mitochondria depending on the amidine substitution.
Lansiaux A; Tanious F; Mishal Z; Dassonneville L; Kumar A; Stephens CE; Hu Q; Wilson WD; Boykin DW; Bailly C
Cancer Res; 2002 Dec; 62(24):7219-29. PubMed ID: 12499262
[TBL] [Abstract][Full Text] [Related]
27. Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin.
Krishna R; St-Louis M; Mayer LD
Int J Cancer; 2000 Jan; 85(1):131-41. PubMed ID: 10585596
[TBL] [Abstract][Full Text] [Related]
28. Induction of apoptosis in neoplastic cells by anthracycline antitumor drugs: nuclear and cytoplasmic triggering?
Serafino A; Sinibaldi-Vallebona P; Pierimarchi P; Bernard P; Gaudiano G; Massa C; Rasi G; Ranagnan G
Anticancer Res; 1999; 19(3A):1909-18. PubMed ID: 10470135
[TBL] [Abstract][Full Text] [Related]
29. A cell fractionation approach for the quantitative analysis of subcellular drug disposition.
Duvvuri M; Feng W; Mathis A; Krise JP
Pharm Res; 2004 Jan; 21(1):26-32. PubMed ID: 14984254
[TBL] [Abstract][Full Text] [Related]
30. Intracellular localization and trafficking of fluorescein-labeled cisplatin in human ovarian carcinoma cells.
Safaei R; Katano K; Larson BJ; Samimi G; Holzer AK; Naerdemann W; Tomioka M; Goodman M; Howell SB
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):756-67. PubMed ID: 15701866
[TBL] [Abstract][Full Text] [Related]
31. Tumor-targeted intracellular delivery of anticancer drugs through the mannose-6-phosphate/insulin-like growth factor II receptor.
Prakash J; Beljaars L; Harapanahalli AK; Zeinstra-Smith M; de Jager-Krikken A; Hessing M; Steen H; Poelstra K
Int J Cancer; 2010 Apr; 126(8):1966-1981. PubMed ID: 19795464
[TBL] [Abstract][Full Text] [Related]
32. Intracellular mapping of 4'-deoxy-4'-iododoxorubicin in sensitive and multidrug resistant cells by electron spectroscopic imaging.
Diociaiuti M; Calcabrini A; Meschini S; Arancia G
Micron; 1997 Oct; 28(5):389-95. PubMed ID: 9519468
[TBL] [Abstract][Full Text] [Related]
33. Analysis of intracellular organelles by flow cytometry or microscopy.
Poot M
Curr Protoc Cytom; 2001 May; Chapter 9():Unit 9.4. PubMed ID: 18770757
[TBL] [Abstract][Full Text] [Related]
34. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin.
Paliwal SR; Paliwal R; Agrawal GP; Vyas SP
J Liposome Res; 2016 Dec; 26(4):276-87. PubMed ID: 26784587
[TBL] [Abstract][Full Text] [Related]
35. Intracellular distribution and pharmacokinetics of daunorubicin in anthracycline-sensitive and -resistant HL-60 cells.
Hindenburg AA; Gervasoni JE; Krishna S; Stewart VJ; Rosado M; Lutzky J; Bhalla K; Baker MA; Taub RN
Cancer Res; 1989 Aug; 49(16):4607-14. PubMed ID: 2545346
[TBL] [Abstract][Full Text] [Related]
36. Novel tetrapeptide, RGDF, mediated tumor specific liposomal doxorubicin (DOX) preparations.
Du H; Cui C; Wang L; Liu H; Cui G
Mol Pharm; 2011 Aug; 8(4):1224-32. PubMed ID: 21630705
[TBL] [Abstract][Full Text] [Related]
37. The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors.
Mayer LD; Dougherty G; Harasym TO; Bally MB
J Pharmacol Exp Ther; 1997 Mar; 280(3):1406-14. PubMed ID: 9067330
[TBL] [Abstract][Full Text] [Related]
38. Visualization of bioavailable liposomal doxorubicin using a non-perturbing confocal imaging technique.
Krishna R; Ghiu G; Mayer LD
Histol Histopathol; 2001 Jul; 16(3):693-9. PubMed ID: 11510957
[TBL] [Abstract][Full Text] [Related]
39. Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248).
Mosure KW; Henderson AJ; Klunk LJ; Knipe JO
Cancer Chemother Pharmacol; 1997; 40(3):251-8. PubMed ID: 9219510
[TBL] [Abstract][Full Text] [Related]
40. Liposome-based intracellular kinetics of doxorubicin in K562/DOX cells.
Xu DH; Gao JQ; Liang WQ
Pharmazie; 2008 Sep; 63(9):646-9. PubMed ID: 18819516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
